303A COLLEGE ROAD EAST, PRINCETON, NJ
Financial Results, Press Release
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Other Events
PDS Biotech Adopts Amended Protocol for Phase 3 Trial with PFS as Primary Endpoint
RdNCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate Cancer
PDS Biotech Gains New U.S. Patent for PDS0101, Extending Market Protection
Announces FDA Alignment on Use of Progression Free Survival (PFS) as Primary Endpoint
Announces New Composition of Matter Patent for PDS0101 in Japan
Q3
Q2
Q1
FY 2024
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Effectiveness Notice
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Definitive Revised Proxy Statement